2-amino-4-[2-(5-diethylphosphono)furanyl]-5-bromothiazole | 261372-77-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-amino-4-[2-(5-diethylphosphono)furanyl]-5-bromothiazole
• 英文别名: 2-Amino-5-bromo-4-[2-(5-diethylphosphono)furanyl]thiazole；5-Bromo-4-(5-diethoxyphosphorylfuran-2-yl)-1,3-thiazol-2-amine
• CAS: 261372-77-4
• 化学式: C₁₁H₁₄BrN₂O₄PS
• 分子量: 381.187
• InChiKey: FALYMIILKZCLPC-UHFFFAOYSA-N

物化性质

• 沸点：
  493.4±45.0 °C(predicted)
• 密度：
  1.62±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  20
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  116
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  2-amino-4-[2-(5-diethylphosphono)furanyl]-5-bromothiazole 生成 2-amino-5-bromo-4-[(5-phosphono)furan-2-yl]thiazole
  参考文献：
  名称：

  Novel bisamidate phosphonate prodrugs

  摘要：

  新颖的双酰胺磷酸酯前药，用于治疗糖尿病和其他与血糖升高相关的疾病的Formula IA:1中的FBPase抑制剂及其用途。

  公开号：

  US20020173490A1
• 作为产物：
  描述：

  (5-acetylfuran-2-yl)phosphonic acid diethyl ester 在 N-溴代丁二酰亚胺(NBS) 、 copper(ll) bromide 作用下， 以 乙醇 、 氯仿 、 乙酸乙酯 为溶剂， 反应 28.25h， 生成 2-amino-4-[2-(5-diethylphosphono)furanyl]-5-bromothiazole
  参考文献：
  名称：

  Discovery of a Series of Phosphonic Acid-Containing Thiazoles and Orally Bioavailable Diamide Prodrugs That Lower Glucose in Diabetic Animals Through Inhibition of Fructose-1,6-Bisphosphatase

  摘要：

  Oral delivery of previously disclosed purine and benzimidazole fructose-1,6 bisphosphatase (FBPase) inhibitors via prodrugs failed, which was likely due to their high molecular wright (> 600) Therefore, a smaller scaffold was desired, and a series of phosphonic acid-containing thiazoles, which exhibited high potency against human liver FBPase (IC(50) of 10-30 nM) and high selectivity relative to other 5'-adenosinemonophosphate (AMP)-binding enzymes, were discovered using a structure-guided drug design approach The initial lead compound (30j) produced profound glucose lowering in rodent models of type 2 diabetes mellitus (T2DM) after parenteral administration Various phosphonate prodrugs were explored without success, until a novel phosphonic diamide prodrug approach was Implemented, which delivered compound 30j with good oral bioavailability (OBAV) (22-47%) Extensive lead optimization of both the thiazole FBPase inhibitors and their prodrugs culminated in the discovery of compound 35n (MB06322) as the first oral FBPase inhibitor advancing to human clinical trials as a potential treatment for T2DM

  DOI：

  10.1021/jm101035x

文献信息

• Combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes
  申请人：Metabasis Therapeutics, Inc.

  公开号：US06756360B1

  公开（公告）日：2004-06-29

  Pharmaceutical compositions containing an FBPase inhibitor and an insulin sensitizer are provided as well as methods for treating diabetes and diseases responding to increased glycemic control, an improvement in insulin sensitivity, a reduction in insulin levels, or an enhancement of insulin secretion.

  提供含有FBPase抑制剂和胰岛素增敏剂的药物组合物，以及治疗糖尿病和对增加糖代谢控制、改善胰岛素敏感性、降低胰岛素水平或增强胰岛素分泌有响应的疾病的方法。
• Discovery of Potent and Specific Fructose-1,6-Bisphosphatase Inhibitors and a Series of Orally-Bioavailable Phosphoramidase-Sensitive Prodrugs for the Treatment of Type 2 Diabetes
  作者：Qun Dang、Srinivas Rao Kasibhatla、K. Raja Reddy、Tao Jiang、M. Rami Reddy、Scott C. Potter、James M. Fujitaki、Paul D. van Poelje、Jingwei Huang、William N. Lipscomb、Mark D. Erion

  DOI：10.1021/ja074871l

  日期：2007.12.1

  discoveries of a low molecular weight inhibitor series with increased potency and a phosphonate prodrug class suitable for their oral delivery. The lead inhibitor, 10A, was designed with the aid of X-ray crystallography and molecular modeling to bind to the allosteric AMP binding site of FBPase. High potency (IC50 = 16 nM) and FBPase specificity were achieved by linking a 2-aminothiazole with a phosphonic

  肝脏产生过多的葡萄糖，加上肌肉、脂肪和肝脏对葡萄糖的摄取和代谢减少，导致 2 型糖尿病患者的血糖水平长期升高。通过减少葡萄糖产生来治疗糖尿病的努力主要集中在糖异生途径和该途径中的限速酶，如果糖-1,6-双磷酸酶 (FBPase)。第一种有效的 FBPase 抑制剂是使用结构引导的药物设计策略 (Erion, MD; et al. J. Am. Chem. Soc. 2007, 129, 15480-15490) 鉴定的，但证明难以口服给药。在此处，我们报告了一系列口服生物可利用 FBPase 抑制剂的合成和表征，这些抑制剂是在结合发现具有增加效力的低分子量抑制剂系列和适合其口服给药的膦酸盐前药类别之后确定的。先导抑制剂 10A 是在 X 射线晶体学和分子建模的帮助下设计的，用于与 FBPase 的变构 AMP 结合位点结合。高效力 (IC50 = 16 nM) 和 FBPase 特异性是通过将
• Discovery of a Series of Phosphonic Acid-Containing Thiazoles and Orally Bioavailable Diamide Prodrugs That Lower Glucose in Diabetic Animals Through Inhibition of Fructose-1,6-Bisphosphatase
  作者：Qun Dang、Yan Liu、Daniel K. Cashion、Srinivas Rao Kasibhatla、Tao Jiang、Frank Taplin、Jason D. Jacintho、Haiqing Li、Zhili Sun、Yi Fan、Jay DaRe、Feng Tian、Wenyu Li、Tony Gibson、Robert Lemus、Paul D. van Poelje、Scott C. Potter、Mark D. Erion

  DOI：10.1021/jm101035x

  日期：2011.1.13

  Oral delivery of previously disclosed purine and benzimidazole fructose-1,6 bisphosphatase (FBPase) inhibitors via prodrugs failed, which was likely due to their high molecular wright (> 600) Therefore, a smaller scaffold was desired, and a series of phosphonic acid-containing thiazoles, which exhibited high potency against human liver FBPase (IC(50) of 10-30 nM) and high selectivity relative to other 5'-adenosinemonophosphate (AMP)-binding enzymes, were discovered using a structure-guided drug design approach The initial lead compound (30j) produced profound glucose lowering in rodent models of type 2 diabetes mellitus (T2DM) after parenteral administration Various phosphonate prodrugs were explored without success, until a novel phosphonic diamide prodrug approach was Implemented, which delivered compound 30j with good oral bioavailability (OBAV) (22-47%) Extensive lead optimization of both the thiazole FBPase inhibitors and their prodrugs culminated in the discovery of compound 35n (MB06322) as the first oral FBPase inhibitor advancing to human clinical trials as a potential treatment for T2DM
• Novel bisamidate phosphonate prodrugs
  申请人：METABASIS THERAPEUTICS, INC.

  公开号：US20020173490A1

  公开（公告）日：2002-11-21

  Novel bisamidate phosphonate prodrugs of FBPase inhibitors of the Formula IA: 1 and their use in the treatment of diabetes and other conditions associated with elevated blood glucose.

  新颖的双酰胺磷酸酯前药，用于治疗糖尿病和其他与血糖升高相关的疾病的Formula IA:1中的FBPase抑制剂及其用途。